Please login to the form below

Emergent BioSolutions

This page shows the latest Emergent BioSolutions news and features for those working in and with pharma, biotech and healthcare.

Emergent inks $174m deal with AstraZeneca to manufacture COVID-19 vaccine

Follows initial deal agreed in June. US-based CDMO Emergent BioSolutions has agreed a deal with AstraZeneca to expand manufacturing of the latter's potential COVID-19 vaccine. ... According to Emergent, the deal is valued at approximately $174m and runs

Latest news

Shake-up at GSK could claim antibiotics unit and UK facilities

In the meantime the company has also announced a product divestment - selling its anthrax prevention drug raxibacumab to Emergent BioSolutions for around $96m. ... The FDA-approved therapy is tied to a $130m supply deal with the US government, which will
GSK: We had a social responsibility to work on Ebola

More recently it was revealed this week that will be working with Emergent BioSolutions on a phase I trial that would addd that firm's Ebola vaccine candidate as a booster
TB vaccine disappoints, but others in the pipeline

Helen McShane of the University of Oxford in the UK. The trial was sponsored by non-profit vaccines company Aeras, the Wellcome Trust and the Oxford-Emergent Tuberculosis Consortium (OETC), a ... joint venture between the University of Oxford and
Biologics buoyant

Phase I . 28. Oxford Biomedica/Emergent BioSolutions. Prime boost technology - vaccines.

More from news
Approximately 1 fully matching, plus 4 partially matching documents found.

Latest Intelligence

Deal Watch table for August 2014

187. Emergent BioSolutions/ Morphosys. Licence, joint development &commercialisation. MOR209/ES414, anti-PSMA/anti-CD3 bi-specific antibody targeting prostate cancer (preclinical).
Deal Watch table for April 2013

60. Bracco Diagnostics/ Emergent BioSolutions. Asset purchase. Healthcare Protective Products Division.
Interview: Charles Mgone, EDCTP

But it doesn't stop the contagious form acquired by adults. So we are working with Emergent BioSolutions and Aeras, a non-profit product developer, as well as institutions in the

More from intelligence
Approximately 0 fully matching, plus 3 partially matching documents found.

Latest appointments

Barry Labinger joins Biothera Pharmaceutical

Labinger has nearly three decades of pharmaceutical and biotech industry experience, with roles at Emergent BioSolutions, Human Genome Sciences, 3M Pharmaceuticals and Immunex. ... Labinger most recently served as executive vice president and president,

More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company

OUTiCO

Providing an exceptional outsourcing service to the Pharma & Healthcare industries. We offer a sustainable approach and drive sales outcomes...

Latest intelligence

InSite Mapping™ - a Novel Tool for Insight-gathering and Patient Journey Mapping: Learn how a client engaged 18 rheumatologist advisors over 6 months to create a patient journey map for SLE....
Alone we can do so little, together we can do so much: Collaboration is at the heart of successful patient engagement and effective healthcare provision. But in such a complex, nuanced network, true collaborations are rare. So how can we, as an...
7 important considerations for creating an inclusive clinical trial website: You might have noticed that all of us here at COUCH Health are big advocates for taking action to improve diversity and inclusion in the world of clinical research. ‘Taking...